NCT01793350 - Safety and Efficacy Study of BC-DN-01 in Painful Diabetic Peripheral Neuropathy | Biotech Hunter

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions

Diabetic Neuropathy, Painful

Interventions

DRUG

BC-DN-01 topically applied cream

Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01

Trial Locations (5)

S10 2JF

Royal Hallamshire Hospital, Sheffield

IP4 5PD

Ipswich Hospital, Ipswich

B9 5SS

Birmingham Heartlands Hospital, Birmingham

M32 0UT

MAC Clinical Research, Manchester

Unknown

Manchester Royal Infirmary, Manchester